Peter Fry

Business Unit Manager, Regulatory Affairs Pharma & Country Manager, UK at QbD Group

Peter Fry is a seasoned expert in regulatory affairs with a strong scientific background in chemistry. At QbD Group, Peter takes up the roles of Business Unit Manager of Regulatory Affairs Pharma and Country Manager UK, supporting clients across the full product lifecycle, with a particular focus on CMC, post-approval changes, and strategic submissions in the EU and UK.

Biography

Peter gained his degree in chemistry from the University of Bristol and began his career as a medicinal chemist, focusing on the research and development of novel GLP-1 secretagogues for the treatment of diabetes and obesity. His work led to several patent applications, where he is named as a co-inventor.

He later transitioned into Regulatory Affairs, joining Mylan (now Viatris) in an Affiliate Support Team role. There, he managed post-approval CMC changes for various markets, especially Germany, working closely with affiliate offices and quality functions. At Wainwright Associates (now Pharmalex), he expanded his expertise across regulatory strategy, electronic publishing, GDP, and CMC.

In 2014, Peter joined EUDRAC and was promoted over time to Regulatory Affairs Director and member of the UK Management Team. Following EUDRAC’s integration into QbD Group in 2022, he took on his current dual role.

Peter has worked with companies of all sizes—from start-ups to large multinationals—on regulatory strategies, due diligence, and early development programs, particularly for orphan and rare disease products. He has successfully supported numerous EU and UK Marketing Authorisation Applications and is highly experienced in lifecycle management, often serving as the primary EMA or MHRA contact for client products.

In addition, Peter has led many CMC development projects, authored expert reports, and acted as project manager in collaborations with contract manufacturing organisations—several of which resulted in timely and successful commercial product launches.

Elemental Impurities - Lab Services - QbD Group (2)

Peter's key areas of expertise

CMC & Regulatory Strategy

Supporting pharmaceutical development and registration with a strong focus on Chemistry, Manufacturing, and Controls.

EU & UK Regulatory Procedures

Expertise in the Centralised Procedure and UK national routes, including new post-Brexit pathways.

Post-Approval & Lifecycle Management

Managing variations, renewals, and regulatory interactions across the EU and UK throughout the product lifecycle.

Collaboration with CMOs

Leading CMC projects and coordinating with contract manufacturers to bring products to market on time.

Explore our expert content

Blog

Can IVDR Be Your Global Regulatory Compass for Market Entry?

The In Vitro Diagnostic Regulation (IVDR) in the EU is widely...

Case study

Validating a Complex Autoclave Load to Enhance Sterilization Efficiency

Discover how QbD Group helped a pharmaceutical facility in Barcelona optimize and validate a complex autoclave load, improving sterilization efficiency and manufacturing flexibility.

Webinar

Pharmacovigilance and Risk Management in Innovative Therapies: A Challenge in Drug Safety

Explore pharmacovigilance in cell, CAR T, and RNA therapies. Join our webinar to tackle tomorrow’s drug safety and risk management challenges.

Webinar

Extractables & Leachables in Pharma: Navigating Evolving Regulations and Toxicological Challenges

This webinar aims to provide a comprehensive overview of Extractables and Leachables (E&L) in pharmaceutical products, highlighting regulatory complexities, toxicological challenges, and practical approaches to study design and risk assessment across the product lifecycle.